Doris Makari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Doris Makari has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Christopher S. Ambrose
BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA
1 shared publication - John P. DeVincenzo
Children’s Foundation Research Institute, Memphis, Tennessee
1 shared publication Kelly J. Henrickson
Medical College of Wisconsin, Milwaukee, WI, USA
1 shared publicationMary Allen Staat
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
1 shared publication- Paul A. Checchia
Texas Children's Hospital, 6621 Fannin Street, Houston, TX, 77030, USA.
1 shared publication Xionghua Wu
Medimmune, Gaithersburg, MD, USA
1 shared publication
Latest Publications
- Open Access
- 6 August 2014
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 54 (6) , 594-597
The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
- 6 August 2014
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 54 (6) , 594-597
Open AccessThe Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
- Open Access
- 6 December 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (3) , 607-614
Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus
Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need for full-season dosing by reviewing the pharmacokinetic properties of palivizumab and RSV hospitalization (RSVH) risk as a function of chronologic age. Precise human palivizumab protective levels are not established. Clinical trials show significant interpatient variability in palivizumab serum trough concentrations. Partial season dosing is associated with increased risk of RSVH. For late-preterm infants, data suggest that the risk of RSVH remains elevated through at least 6 months of age. Monthly, full-season palivizumab dosing provides the only empirically proven protection from RSVH. In conclusion, late-preterm infants are at significant risk for RSVH through at least 6 months of age and would benefit from dosing throughout the RSV season.
- 6 December 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (3) , 607-614
Open AccessRationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus
Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need for full-season dosing by reviewing the pharmacokinetic properties of palivizumab and RSV hospitalization (RSVH) risk as a function of chronologic age. Precise human palivizumab protective levels are not established. Clinical trials show significant interpatient variability in palivizumab serum trough concentrations. Partial season dosing is associated with increased risk of RSVH. For late-preterm infants, data suggest that the risk of RSVH remains elevated through at least 6 months of age. Monthly, full-season palivizumab dosing provides the only empirically proven protection from RSVH. In conclusion, late-preterm infants are at significant risk for RSVH through at least 6 months of age and would benefit from dosing throughout the RSV season.